484 related articles for article (PubMed ID: 31605014)
1. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
[TBL] [Abstract][Full Text] [Related]
2. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
3. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
4. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D; Ruan Y; Zhou X
Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
6. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
7. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
8. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
9. Cleavage and polyadenylation-specific factor 3 induces cell cycle arrest via PI3K/Akt/GSK-3β signaling pathways and predicts a negative prognosis in hepatocellular carcinoma.
Li N; Jiang S; Fu R; Lv J; Yao J; Mai J; Hua X; Chen H; Liu J; Lu M
Biomark Med; 2021 Apr; 15(5):347-358. PubMed ID: 33666519
[No Abstract] [Full Text] [Related]
10. T-lymphoma invasion and metastasis 1 promotes invadopodia formation and is regulated by the PI3K/Akt signaling pathway in hepatocellular carcinoma.
Wang B; Zheng B; Cao L; Liao K; Huang D; Zhang Y; Jiang Y; Zheng S
Exp Cell Res; 2021 Oct; 407(2):112806. PubMed ID: 34487727
[TBL] [Abstract][Full Text] [Related]
11. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression.
Xia L; Huang W; Tian D; Zhang L; Qi X; Chen Z; Shang X; Nie Y; Wu K
Hepatology; 2014 Mar; 59(3):958-73. PubMed ID: 24005989
[TBL] [Abstract][Full Text] [Related]
13. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
[TBL] [Abstract][Full Text] [Related]
14. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
15. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D
J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431
[TBL] [Abstract][Full Text] [Related]
16. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
18. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
19. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
20. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.
Lan Y; Han J; Wang Y; Wang J; Yang G; Li K; Song R; Zheng T; Liang Y; Pan S; Liu X; Zhu M; Liu Y; Meng F; Mohsin M; Cui Y; Zhang B; Subash S; Liu L
Cell Death Dis; 2018 Feb; 9(2):236. PubMed ID: 29445189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
